title: [Antiretroviral therapy 2003. The current status].
abstract: In the year 2003, the basis of antiretroviral treatment comprising nucleoside and nucleotide reverse transcriptase inhibitors (NRTI, NNRTI, NtRTI) and protease inhibitors (PI) will be extended to include entry inhibitors (EI). A representative of this class of drugs, enfurvitide (T20), is about to receive official approval. In the meantime, initial data on long-term treatment with tenofovir, which has been available in Germany since February 2002, have become available. Further medications are in the pipe-line of clinical development, for example, the NRTI emtricitabine (FTC) and the Pis amdoxovir and Atazanavir. Results from studies employing immunomodulatory approaches have so far proved disappointing. In contrast, a number of smaller studies on vaccination have provided promising data. Recommendations for antiretroviral treatment of HIV infection were updated in the summer of 2002.
authors.affiliation: Medizinische Klinik, Klinikum Salzgitter.
authors.forename: H
authors.initials: H
authors.lastname: Jablonowski
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005194:Family Practice; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents